We are
De Motu Cordis
Our Mission
To deliver life-saving medicine faster when every second counts
OUR PURPOSE
We relentlessly seek new technologies that will save lives and improve outcomes for patients facing life-threatening emergencies
OUR STORY
We’re an Australian clinical stage pharma company that pursues innovative product platforms for the emergency treatment of life-threatening conditions.
We were founded in Brisbane by ground breaking intensive care specialist and researcher, Professor John F Fraser. He understands the impact that anaphylaxis and cardiac arrest has on a patient’s outcomes and quality of life.
At DMC we see a critical need to deliver life-saving drugs faster to patients when they’re experiencing life-threatening situations outside of hospital.
So we’ve developed a needle-free device for people experiencing anaphylaxis. It has been re-engineered and re-formulated to save lives when every second counts.
Corporate Achievement
2019
- Hire team
- Appoint governing board
2020
- Secured BDF funding and R&D Tax Incentives
- Open new office premises
2021
- Established QMS and cyber resilience
- Seed capital, expanded facilities
- Selected for BEDA Global Medtech Accelerator program
2023
- Presented DMC progress at RESI conference, JP Morgan week, San Francisco
Product Development
2018
- Texas Medical Centre Accelerator Program
2020
- California Life Sciences Institute FAST Program, TIQ sponsorship
- Successful API particle engineering
- US Patent granted
2021
- Formulation developed for rapid Tmax via the lung
- GMP manufacture for Phase 1
2022
- Completion of testing for non-clinical program
- Successful first human clinical study
- Completion of Institutional Review Board (IRB) approved quantitative market research
- EU patent granted
2022
- Pre-IND/FDA engagement
- US based commercial CDMO onboarded
- DMC-IH1 in vitro DPI device performance exceeds industry benchmark
- Completed formative Human Factors (HF) study